



(51) International Patent Classification:

G01N 33/48 (2006.01) *G06F 19/12* (2011.01)
G01N 33/53 (2006.01)

(21) International Application Number:

PCT/US2012/054323

(22) International Filing Date:

7 September 2012 (07.09.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/650,462 22 May 2012 (22.05.2012) US

(71) Applicant (for all designated States except US): **BERG PHARMA LLC** [US/US]; 1845 Elm Hill Pike, Nashville, TN 37210 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NARAIN, Niven, Rajin** [US/US]; 350 Third Street, Suite 2005, Cambridge, MA 02142 (US). **SARANGARAJAN, Rangaprasad** [US/US]; 454 Central Street, Boylston, MA 01505 (US). **VISHNUDAS, Vivek, K.** [IN/US]; 91 Staniford Street, Apt. #1, Newton, MA 02466 (US).(74) Agents: **HANLEY, Elizabeth, A.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: INTERROGATORY CELL-BASED ASSAYS FOR IDENTIFYING DRUG-INDUCED TOXICITY MARKERS




Fig. 7

(57) Abstract: Described herein is a discovery Platform Technology for analyzing a drug- induced toxicity condition, such as cardiotoxicity via model building.